Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales

Short Title: Vascular diseases after COVID-19

Authors

Rochelle Knight MSc^{1,2,3,4*}, Venexia Walker PhD^{1,4*}, Samantha Ip PhD^{5*}, Jennifer A Cooper PhD^{1,2}, Thomas Bolton PhD^{5,6,7,8}, Spencer Keene MSc^{5,6}, Rachel Denholm^{1,2,9}, Ashley Akbari MSc¹⁰, Hoda Abbasizanjani PhD¹⁰, Fatemeh Torabi MSc¹⁰, Efosa Omigie BEng MSc¹¹, Sam Hollings PhD¹¹, Teri-Louise North PhD¹, Renin Toms PhD¹, Emanuele Di Angelantonio FRCP^{5,6,12,13}, Spiros Denaxas PhD^{14,15,16,17}, Johan H Thygesen¹⁴, Christopher Tomlinson MBBS¹⁴, Ben Bray MD¹⁸, Craig J Smith MD MRCP^{19,20}, Mark Barber MD²¹, George Davey Smith MD FRS^{1,4}, Nishi Chaturvedi MD²², Cathie Sudlow FRSE^{7,8}, William N Whiteley FRCP^{*23,24}, Angela Wood PhD^{*5,6,10,11,25}, Jonathan A C Sterne PhD^{*1,2,7}, for the CVD-COVID-UK/COVID-IMPACT consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study.

1. Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
2. NIHR Bristol Biomedical Research Centre, Bristol, UK.
3. NIHR Applied Research Collaboration West, Bristol, UK
4. MRC Integrative Epidemiology Unit, Bristol, UK
5. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
6. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
7. BHF Data Science Centre
8. Health Data Research UK
9. Health Data Research UK South-West, Bristol, UK
10. Population Data Science, Health Data Research UK, Swansea University
11. NHS Digital
12. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
13. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
14. Institute of Health Informatics, University College London
15. Health Data Research UK, University College London, London, UK
16. NIHR University College London Hospitals Biomedical Research Centre, London, UK
17. BHF Accelerator, London, UK
18. School of Population Health and Environmental Sciences, King's College London
19. Geoffrey Jefferson Brain Research centre, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford Royal Hospital, Salford
20. Division of Cardiovascular Sciences, University of Manchester
21. Glasgow Caledonian University
22. MRC Unit for Lifelong Health and Ageing at UCL, Institute of Cardiovascular Science, University College London, London, U.K.
23. Centre for Clinical Brain Sciences, University of Edinburgh
24. Nuffield Department of Population Health University of Oxford
25. NIHR Cambridge Biomedical Research Centre

*Drs Walker, Knight and Ip contributed equally. Drs Whiteley, Wood, and Sterne contributed equally.

Corresponding author

Jonathan A C Sterne, Population Health Sciences, Bristol Medical School, University of Bristol, UK.

Email: jonathan.sterne@bristol.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Word count: 3121

Key points

Question

Is COVID-19 associated with higher long-term incidence of vascular diseases?

Findings

In this cohort study of 48 million adults in England and Wales, COVID-19 was associated with higher incidence, that declined with time since diagnosis, of both arterial thromboses [week 1: adjusted HR [aHR] 21.7 (95% CI 21.0-22.4) weeks 27-49: aHR 1.34 (1.21-1.48)] and venous thromboembolism [week 1: aHR 33.2 (31.3-35.2), weeks 27-49 1.80 (1.50-2.17)]. aHRs were higher, for longer, after hospitalised than non-hospitalised COVID-19. The estimated excess number of arterial thromboses and venous thromboembolisms was 10,500.

Meaning

Avoidance of COVID-19 infection through vaccination, and use of secondary preventive agents after infection in high-risk patients, may reduce post-COVID-19 acute vascular diseases.

Abstract

Importance: The long-term effects of COVID-19 on the incidence of vascular diseases are unclear.

Objective: To quantify the association between time since diagnosis of COVID-19 and vascular disease, overall and by age, sex, ethnicity, and pre-existing disease.

Design: Cohort study based on population-wide linked electronic health records, with follow up from January 1st to December 7th 2020.

Setting and participants: Adults registered with an NHS general practice in England or Wales and alive on January 1st 2020.

Exposures: Time since diagnosis of COVID-19 (categorised as 0-6 days, 1-2 weeks, 3-4, 5-8, 9-12, 13-26 and 27-49 weeks since diagnosis), with and without hospitalisation within 28 days of diagnosis.

Main outcomes and measures: Primary outcomes were arterial thromboses (mainly acute myocardial infarction and ischaemic stroke) and venous thromboembolic events (VTE, mainly pulmonary embolism and lower limb deep vein thrombosis). We also studied other vascular events (transient ischaemic attack, haemorrhagic stroke, heart failure and angina). Hazard ratios were adjusted for demographic characteristics, previous disease diagnoses, comorbidities and medications.

Results: Among 48 million adults, 130,930 were and 1,315,471 were not hospitalised within 28 days of COVID-19. In England, there were 259,742 first arterial thromboses and 60,066 first VTE during 41.6 million person-years follow-up. Adjusted hazard ratios (aHRs) for first arterial thrombosis compared with no COVID-19 declined rapidly from 21.7 (95% CI 21.0-22.4) to 3.87 (3.58-4.19) in weeks 1 and 2 after COVID-19, 2.80 (2.61-3.01) during weeks 3-4 then to 1.34 (1.21-1.48) during weeks 27-49. aHRs for first VTE declined from 33.2 (31.3-35.2) and 8.52 (7.59-9.58) in weeks 1 and 2 to 7.95 (7.28-8.68) and 4.26 (3.86-4.69) during weeks 3-4 and 5-8, then 2.20 (1.99-2.44) and 1.80 (1.50-2.17) during weeks 13-26 and 27-49 respectively. aHRs were higher, for longer after diagnosis, after hospitalised than non-hospitalised COVID-19. aHRs were also higher among people of Black and Asian than White ethnicity and among people without than with a previous event. Across the whole population estimated increases in risk of arterial thromboses and VTEs were 2.5% and 0.6% respectively 49 weeks after COVID-19, corresponding to 7,197 and 3,517 additional events respectively after 1.4 million COVID-19 diagnoses.

Conclusions and Relevance: High rates of vascular disease early after COVID-19 diagnosis decline more rapidly for arterial thromboses than VTEs but rates remain elevated up to 49 weeks after COVID-19. These results support continued policies to avoid COVID-19 infection with effective COVID-19 vaccines and use of secondary preventive agents in high-risk patients.

98 Introduction

99 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of COVID-
100 19, induces a pro-thrombotic and pro-inflammatory state that may increase the risk of serious
101 thrombotic disorders.¹ Most previous studies suggest immediate marked increases in both arterial
102 (largely MI and stroke), and venous thromboembolic events (VTEs),²⁻⁸ although these might be
103 exaggerated due to universal testing for COVID-19 in all hospital admissions. However, few studies
104 have quantified long term vascular risks after diagnosis of COVID-19 or explored how these risks
105 differ by key characteristics such as age, sex, ethnicity, or pre-existing disease.

106 Anonymised population-scale linked primary and secondary care electronic health records (EHRs) for
107 the whole population of England and Wales were analysed to estimate the relative incidence of
108 major arterial thromboses and VTEs up to one year after COVID-19 diagnosis, compared with people
109 without COVID-19, accounting for multiple potential confounding factors. Variation in relative
110 incidence by COVID-related hospitalisation and demographic factors was examined.

Methods

Population

Pseudonymised data on adults alive and registered with a primary care general practice in England or Wales on 1st January 2020 were accessed and analysed, within NHS Digital's secure, privacy protecting Trusted Research Environment (TRE) Service for England and the SAIL databank for Wales.^{9,10} The TRE for England includes primary care data (GPES data for Pandemic Planning and Research, GPPR) from 98% of general practices linked at individual-level to secondary care data including all NHS hospital admissions, critical care, emergency department and outpatient episodes (Hospital Episode Statistics and Secondary Uses Service data from 1997 onwards), COVID-19 laboratory testing data, national community drug dispensing data (NHS BSA Dispensed Medicines from 2018) and death registrations. The SAIL databank includes data from hospital admissions, mortality registers, primary care, COVID-19 test results, community dispensing, and critical care, enabled through the C19_Cohort20 platform.¹¹

COVID-19 diagnosis

COVID-19 diagnosis was defined as a record of a positive COVID-19 polymerase chain reaction (PCR), or antigen test, or a confirmed COVID-19 diagnosis in primary care or secondary care hospital admission records and derived the earliest date on which COVID-19 was recorded (Supplementary Table 1). 'Hospitalisation for COVID-19' was defined as a hospital admission record with confirmed COVID-19 diagnosis in the primary position within 28 days of first COVID-19 diagnoses and 'COVID-19 without hospitalisation' as a COVID-19 diagnosis without such hospitalisation.

Outcomes

Outcomes were defined using primary care, hospital admission and national death registry data (Supplementary Table 2). Specialist clinician-verified SNOMED-CT, Read code and ICD-10 rule-based phenotyping algorithms were used to define fatal or non-fatal: (i) arterial thromboses (myocardial infarction (MI), ischaemic stroke (ischaemic or unclassified stroke, spinal stroke or retinal infarction), and other non-stroke non-MI arterial thromboembolism); (ii) VTEs (pulmonary embolism (PE), lower limb deep venous thrombosis (DVT), other DVT, portal vein thrombosis and intracranial venous thrombosis (ICVT)); and (iii) other vascular events (transient ischaemic attack (TIA), haemorrhagic stroke (intracerebral or subarachnoid haemorrhage), heart failure and angina).

Potential confounding variables

Primary and secondary care records up to 1st January 2020 were used to define ethnicity, deprivation, smoking status and region. A large number of potentially confounding variables were defined based on previous disease diagnoses, comorbidities and medications (Supplementary Table 3).

Statistical Analyses

Hazard ratios (HRs) were estimated for time since diagnosis of COVID-19 (categorised as 0-6 days, 1-2 weeks, 3-4, 5-8, 9-12, 13-26 and 27-49 weeks since diagnosis), compared with follow up without or before diagnosis of COVID-19 (reference group). Analyses used Cox regression models with calendar time scale (starting on 1st January 2020), to account for rapid changes in incidence rates during the pandemic, fitted separately by age group (categorised as <40, 40-59, 60-79 and ≥80 years on 1st January 2020) and by population (England and Wales). Censoring was at the earliest of the date of the outcome, death, or 7th December 2020 (the day before the UK COVID-19 vaccine rollout started). For computational efficiency, analyses included all people with the outcome of interest or with a record of COVID-infection, and a 10% randomly sampled subset of other people. Analyses incorporated inverse probability weights with robust standard errors to account for this sampling. Overall HRs were combined across age groups using inverse-variance weighted meta-analyses.

Crude; age, sex and region-adjusted; and maximally adjusted HRs were estimated: the latter controlled for all the potential confounders listed in Supplementary Table 3. Where necessary in subgroup analyses, potential confounders with ≤ 2 disease events at any level were excluded. In subgroup analyses for which there were no outcome events in one or more time periods post-COVID-19 diagnosis the time periods were collapsed into categories “1-4” and “>5” weeks since COVID-19.

Separate analyses were conducted after hospitalised and non-hospitalised COVID-19. For the combined arterial thrombosis and VTE outcomes, additional subgroup analyses were conducted by sex, ethnicity and history of arterial thrombosis and VTE respectively. Because of the smaller population size, analyses of Welsh data excluded the <40 years age group, were restricted to all COVID-19 diagnoses and the combined arterial thrombosis and VTE outcomes, and were conducted separately only by sex. Results were combined across the English and Welsh populations using inverse-variance weighted meta-analyses. Further details of the statistical analyses are provided in the supplementary material.

The average daily incidence of major arterial and venous events before or in the absence of COVID-19 was calculated across the whole follow up period, separately in subgroups defined by age and sex. These were multiplied by the maximally adjusted age- and sex-specific HR for that day to derive the incidence on each day after COVID-19. A life table approach was used to calculate age- and sex-specific cumulative risks over time with and without COVID-19 and latter was subtracted from the former to derive the absolute excess risks over time after COVID-19, compared with no COVID-19 diagnosis. Overall absolute excess risk was estimated from a weighted sum of the age and sex-specific excess risks, weighted by the proportions of people in age and sex strata within the COVID-19 infected population in England during the follow-up period.

Study oversight

Approval was obtained from the Newcastle & North Tyneside 2 Research Ethics Committee (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC 381078-Y9C5K) and the British Heart Foundation Data Science Centre CVD-COVID UK Approvals and Oversight Board. Pseudonymised data was accessed and analysed within privacy protecting trusted research environments. The analysis was performed according to a pre-specified analysis plan with phenotyping and analysis code at github.com/BHFDSC/CCU002_01. Analyses used SQL, Python and RStudio (Professional) Version 1.3.1093.1 driven by R Version 4.0.3 (2020-10-10).

Results

Among 44,964,486 people in the England population, 118,879 (264/100,000) were hospitalised with COVID-19 and 1,248,810 (2,776/100,000) were not hospitalised within 28 days of their COVID-19 diagnosis (Table 1). Among 2,615,854 people in the Wales population 12,051 and 66,661 respectively were hospitalised and not hospitalised after COVID-19 (Supplementary Table 4).

The risk of non-hospitalised COVID-19 was higher in women than men (3,110 versus 2,428/100,000), but the risk of hospitalised COVID-19 was higher in men than women (304 versus 226/100,000) (Table 1). As expected, the risk of hospitalised COVID-19 increased markedly with increasing age, from 28.3/100,000 at age 18-29 years to 1,944/100,000 at age 90+ years. By contrast the risk of non-hospitalised COVID-19 was higher (3,816 and 4,749/100,000) in these youngest and oldest age groups and lowest (1,450/100,000) in those aged 70-79 years. The risks of both hospitalised and non-hospitalised COVID-19 increased with increasing index of multiple deprivation.

Numbers of arterial thromboses, VTEs and other vascular events before COVID-19 and after hospitalised and non-hospitalised COVID-19, in the England population are shown in Table 2. Of 259,742 arterial thromboses, 2,246 and 5,150 were after hospitalised and non-hospitalised COVID-19 respectively. Corresponding figures for VTEs were 60,066, 810 and 1,812. Most arterial thromboses were either acute myocardial infarction (MI, 129,429) or ischaemic stroke (128,340) and most VTEs were either pulmonary embolism (PE, 32,153) or lower limb deep vein thrombosis (DVT, 25,590). The proportion of strokes due to haemorrhage was as expected (9.2% after hospitalised COVID-19 and 15% after non-hospitalised COVID-19). The total person-years of follow up in the England population were 41,595,372 before COVID-19, 32,471 after hospitalised COVID-19 and 245,817 after non-hospitalised COVID-19. Corresponding figures in the Wales population were 2,383,967, 3,048 and 10,961.

Across outcomes and all time periods after COVID-19, maximally adjusted hazard ratios (aHRs) were attenuated compared with unadjusted hazard ratios (Figure 1, Supplementary Table 5). aHRs for acute myocardial infarction (AMI) declined rapidly from 17.2 (95% CI 16.3-18.1) in week 1 to 1.21 (1.03-1.41) in weeks 27-49. They were higher, for longer after diagnosis, after hospitalised compared with non-hospitalised COVID-19: aHRs during weeks 27-49 were 1.39 (1.12-1.72) and 1.03 (0.83-1.28) respectively (Supplementary Figure 1). aHRs for ischaemic stroke were higher than for MI: they declined from 28.1 (26.8-29.4) in week 1 to 1.62 (1.42-1.86) in weeks 27-49, at which time they were 1.62 (1.33-1.98) and 1.33 (1.10-1.59) after hospitalised and non-hospitalised COVID-19 respectively.

Rates of DVT and PE were elevated for longer after diagnosis of COVID-19 than those for arterial thromboses: aHRs compared with no COVID-19 were 4.80 (95% CI 4.03-5.73) and 10.5 (9.44-11.8) respectively 3-4 weeks after diagnosis, declining to 1.62 (1.42-1.86) and 1.99 (1.49-2.65) in weeks 27-49, by which time aHRs were similar for hospitalised and non-hospitalised COVID-19. Overall aHRs for haemorrhagic stroke declined to below 2 by 3-4 weeks after diagnosis, but peaked again (aHR 4.85 [3.01-7.81]) 9-12 weeks after hospitalised COVID-19. aHRs for angina and heart failure declined rapidly and were below 1.5 by 13-26 weeks after diagnosis.

For the first (of any) arterial thrombosis, aHRs compared with no COVID-19 declined rapidly from 21.7 (95% CI 21.0-22.4) to 3.87 (3.58-4.19) between the first and second weeks after COVID-19 to 2.80 (2.61-3.01) during weeks 3-4 and then more gradually to 1.34 (1.21-1.48) during weeks 27-49 (Figure 2, supplementary Table 6). aHRs were higher after hospitalised than non-hospitalised COVID-19 from week 2 (6.60 [5.85-7.44] versus 2.65 [2.37-2.96]) onwards declining to 1.46 (1.26-1.70) versus 1.21 (1.05-1.40) by weeks 27-49. During weeks 1-4 aHRs were greater in those with no prior history of an arterial thrombosis (12.1 [11.5-12.8]), compared to those with a prior history (6.21 [5.30-7.27]), an effect that attenuated with duration of follow up. There were no consistent differences between age groups. aHRs were marginally greater in males than females. aHRs were greater in people of Black or Black British ethnicity (10.4 [95% CI 8.70-12.5] and 1.96 [1.60-2.41]

during weeks 1-4 and 5-49 respectively) and people of Asian or Asian British ethnicity (9.35 [8.48-10.30] and 1.64 [1.43-1.89] respectively) than those of White ethnicity (7.66 [7.42-7.92] and 1.47 [1.40-1.53] respectively).

For the first VTE, aHRs after COVID-19 compared with no COVID-19 declined more gradually than those for arterial thromboses, from 33.2 (95% CI 31.3-35.2) and 8.52 (7.59-9.58) in the first and second weeks to 7.95 (7.28-8.68) and 4.26 (3.86-4.69) during weeks 3-4 and 5-8, then more gradually to 2.20 (1.99-2.44) and 1.80 (1.50-2.17) during weeks 13-26 and 27-49 respectively (Figure 3, Supplementary Table 7). aHRs for venous events were substantial for the first 8 weeks following hospitalised COVID-19 (11.2 [9.72-12.9] during weeks 5-8 then 5.40 [4.31-6.77], 2.63 [2.19-3.14] and 1.57 [1.14-2.16] during weeks 9-12, 13-26 and 27-49 respectively. Following non-hospitalised COVID-19, aHRs were 2.56 (2.22-2.95), 2.22 (1.84-2.68), 1.98 (1.74-2.25) and 1.77 (1.38-2.27) during weeks 5-8, 9-12, 13-26 and 27-49 respectively. aHRs were greater in those without than with a prior history of a venous event, but did not differ markedly between age groups. aHRs in males were greater than those in females during weeks 1-4 after COVID-19. aHRs were higher in people of Black or Black British ethnicity (18.0 [14.3-22.8] and 2.68 [1.94-3.70] during weeks 1-4 and 5-49 respectively) and people of Asian or Asian British ethnicity (17.6 [14.2-21.8] and 4.05 [3.09-5.31] respectively) than those of White ethnicity (10.1 [9.56-10.7] and 2.49 [2.32-2.66] respectively).

Absolute excess risks were generally greater in men and in older patients (Figure 4). Combining all arterial thromboses, the excess risk 49 weeks after diagnosis of COVID-19 ranged from 2.3% and 1.7% respectively in men and women aged ≥ 80 years to 0.03% and 0.01% respectively in men and women aged < 40 years (Figure 4). Combining all VTE events, the excess risk at 49 weeks ranged from 0.6% in men and women aged ≥ 80 years to 0.1% in men and women aged < 40 years. Excluding events in the first 28 days approximately halved these absolute excess risks (Supplementary Figure 2). Across the whole population, the estimated absolute increases in the risk of arterial thromboses and VTEs were 0.5% and 0.25% respectively. This corresponds to 7,200 and 3,500 additional arterial thromboses and VTEs respectively after 1.4 million COVID-19 diagnoses.

Discussion

In this cohort of 48 million adults, markedly higher relative incidence of arterial thromboses in the first weeks after COVID-19 diagnosis, relative to no COVID-19 diagnosis, declined rapidly. High relative incidence of VTEs in the first weeks after COVID-19 diagnosis declined less rapidly than for arterial thromboses, and remained 2-fold higher up to 49 weeks post COVID-19 diagnosis. For both arterial thromboses and VTEs, relative incidence was higher, and remained elevated for longer, after hospitalised than non-hospitalised COVID-19. Associations did not vary markedly by age or sex, but were greater in people of Black or Asian ethnicity than those of White ethnicity, and in people without than with a prior history of vascular events. By December 2020, COVID-19 led to over 10,500 additional arterial thromboses and VTEs in England and Wales.

As we included almost all of the adult English and Welsh populations, the results reflect the total population impact of COVID-19 on the incidence of major vascular events, and are generalisable to other settings with comprehensive healthcare. Linkage with primary care records and national COVID-19 testing data allowed us to study vascular diseases after both hospitalised and non-hospitalised COVID-19, and adjust for a wide range of potentially confounding factors. We used a widely agreed set of codes in EHRs to identify arterial thromboses and VTEs recorded in the first position in hospital and death records. The protocol was prespecified and all code lists are available.

Like other studies of vascular disease risk after COVID-19 infection,^{4,7,8,14} this study found that incidence of arterial thromboses and VTEs was markedly elevated in the first 1-2 weeks after COVID-19 diagnosis, and declined with time from diagnosis. Two self-controlled case series found that excluding cases of arterial or venous events recorded on the first day of COVID-19 diagnosis attenuated the early relative incidence associated with COVID-19.^{4,7} This may have been due to ascertainment of COVID-19 at the time of hospitalisation for a vascular event, or to limited resolution of date coding of COVID and vascular events in the same hospital admission.

Incidence of arterial thromboses and VTEs is also elevated after non-COVID-19 infections. In general, the relative increases are greatest soon after infection and fall within a month towards baseline, although elevated incidence of VTEs may persist for longer. These relative increase after other infections was similar to this study's estimates 2 weeks after COVID-19 diagnosis.^{13,15-17}

Hospital admissions due to MI¹⁸ and stroke¹⁹ fell during the height of the COVID-19 pandemic in England and Wales. This suggests any increase in hospitalisations for arterial thromboses or VTEs after COVID-19 is small compared with the substantial reductions in diagnoses and healthcare use during the early stages of the pandemic.

The estimates of the increased absolute risk of arterial thromboses and VTEs after a single COVID-19 infection are small, at most 2.3% in men and 1.7% in women aged ≥80 years. Nonetheless, the large number of COVID-19 infections in England and Wales during 2020 is likely to have caused a substantial additional burden of arterial thromboses and VTEs. Preventive strategies after COVID-19 might be important at a population level, if they do not substantially increase the risk of adverse events such as bleeding. Observational studies suggest a protective effect of statin and blood pressure lowering.^{20,21} Randomised trials of short courses of antithrombotic interventions with a low risk of harm might be the next step, although the largest study of aspirin in patients hospitalised with COVID-19 showed the reduction in thrombotic events was similar to the increase in haemorrhagic events.²² Studies of aspirin in non-hospitalised patients with COVID-19 are ongoing. To avoid post-COVID-19 thrombotic events, policy responses should include avoiding severe COVID-19 infection through population-wide use of effective COVID-19 vaccines, and use of existing secondary preventative agents in patients with a prior history of stroke or MI.

This study has several limitations. First, the survival analyses allowed for variations in diagnoses with calendar time, so should control for the reductions in hospital attendance the period of maximum

disruption (March and April 2020). However, some vascular events not have been recorded either because patients died in nursing homes with few diagnostic resources, or were so unwell that MI, stroke, PE or DVT diagnoses would have been difficult. Second, patients may have avoided healthcare after minor vascular events because of fear of COVID-19. If this was more likely in people without COVID-19, then estimated hazard ratios would have been biased upwards. Third, because the English primary care dataset did not include information on PE and DVT, the incidence of milder venous events may have been underestimated.

Fourth, we had limited resolution to determine the date order of COVID diagnosis and arterial thromboses or VTE events for some hospitalised patients. Some patients hospitalised with a vascular event either developed a nosocomial infection or had a COVID-19 diagnosis after routine testing on admission. For some patients, a raised troponin with COVID-19 may have led to a diagnosis of MI.¹² Therefore the very high hazard ratios within one week of COVID-19 diagnosis may have been inflated by reverse causality. Fifth, there was under-ascertainment of COVID-19 infection before testing for SARS-CoV-2 became widely available for mild or asymptomatic infections. Such underdiagnosis would bias estimated post-COVID hazard ratios towards the null.

Sixth, unmeasured confounding may explain some findings, since there is a substantial overlap between risk factors for vascular disease and COVID-19. Risk factors for vascular events (e.g. body mass index) are not systematically recorded for all patients, and are subject to measurement error. The difference between adjusted and unadjusted hazard ratios was more marked longer after COVID-19 diagnosis: the hazard ratios for major arterial events more than 13 weeks (HR 1.3) after diagnosis could be due to unmeasured confounding. However the higher hazard ratios for venous events after 13 weeks are less plausibly explained by unmeasured confounding, and are consistent with the risk of venous events after other infections.¹³

In conclusion, substantial increases in the relative incidence of arterial thromboses and VTE events 1-2 weeks after diagnosis of COVID-19 decline with time since diagnosis, although doubling of the incidence of VTE events persisted up to 49 weeks after diagnosis. These results support continued policies to avoid COVID-19 infection with effective COVID-19 vaccines and use of secondary preventive agents in high-risk patients.

Data sharing

Data used in this study are available in NHS Digital's Trusted Research Environment (TRE) for England, but as restrictions apply they are not publicly available (<https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-environment-service-for-england>). The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre (<https://www.hdruc.ac.uk/helping-with-health-data/bhf-data-science-centre/>) received approval to access data in NHS Digital's TRE for England from the Independent Group Advising on the Release of Data (IGARD) (<https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data>) via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (<https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services>). The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (<https://www.hdruc.ac.uk/projects/cvd-covid-uk-project/>) subsequently granted approval to this project to access the data within the TRE for England and the Secure Anonymised Information Linkage (SAIL) Databank. The de-identified data used in this study was made available to accredited researchers only.

Data used in this study are available in the SAIL Databank at Swansea University, Swansea, UK, but as restrictions apply they are not publicly available. All proposals to use SAIL data are subject to review by an independent Information Governance Review Panel (IGRP). Before any data can be accessed, approval must be given by the IGRP. The IGRP gives careful consideration to each project to ensure proper and appropriate use of SAIL data. When access has been granted, it is gained through a privacy protecting data safe haven and remote access system referred to as the SAIL Gateway. SAIL has established an application process to be followed by anyone who would like to access data via SAIL at <https://www.saildatabank.com/application-process>.

Acknowledgements

This study makes use of de-identified data held in NHS Digital's Trusted Research Environment for England and made available via the BHF Data Science Centre's CVD-COVID-UK/COVID-IMPACT consortium. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make health relevant data available for research.

This study makes use of anonymised data held in the Secure Anonymised Information Linkage (SAIL) Databank. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research. We wish to acknowledge the collaborative partnership that enabled acquisition and access to the de-identified data, which led to this output. The collaboration was led by the Swansea University Health Data Research UK team under the direction of the Welsh Government Technical Advisory Cell (TAC) and includes the following groups and organisations: the SAIL Databank, Administrative Data Research (ADR) Wales, Digital Health and Care Wales (DHCW), Public Health Wales, NHS Shared Services Partnership (NWSSP) and the Welsh Ambulance Service Trust (WAST). All research conducted has been completed under the permission and approval of the SAIL independent Information Governance Review Panel (IGRP) project number 0911.

Author contributions

WW conceived the study. WW, AW, RD, JAC, CS and JACS drafted the protocol. JACS, AW, VW, JAC and RD designed the statistical analyses. RK, VW, SI, TB, SK, AA, HA, FT, EO, SH, SD, JHT and CT developed codelists and derived datasets. SD, JHT and CT created electronic health record phenotyping algorithms for hospitalised and non-hospitalised COVID-19. RK, VW, SI, JAC, TB, SK, RD,

AA, HA, FT, TLN, RT, SD, JHT, CT and AW conducted statistical analyses. JACS, WW, AW, VW, RK and SI produced the first draft of the manuscript. CS is Director of the BHF Data Science Centre and coordinated approvals for and access to data within the NHS Digital TRE and the SAIL Databank TRE for CVD-COVID-UK/COVID-IMPACT. All authors critically appraised the manuscript for important intellectual content and contributed to the final draft of the manuscript.

Funding

This work was funded by the Longitudinal Health and Wellbeing COVID-19 National Core Study, which was established by the UK Chief Scientific Officer in October 2020 and funded by UK Research and Innovation (grant references MC_PC_20030 and MC_PC_20059), by the British Heart Foundation as part of the BHF Data Science Centre led by HDR UK (BHF grant number SP/19/3/34678), by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant reference MC_PC_20058), and by the CONVALESCENCE study of long COVID, which is funded by NIHR/UKRI. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research. This work was supported by the Con-COV team funded by the Medical Research Council (grant number: MR/V028367/1). This work was supported by Health Data Research UK, which receives its funding from HDR UK Ltd (HDR-9006) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust. This work was supported by core funding from the: British Heart Foundation (BHF; RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/13/6/30180) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. This work was supported by the ADR Wales programme of work. The ADR Wales programme of work is aligned to the priority themes as identified in the Welsh Government's national strategy: Prosperity for All. ADR Wales brings together data science experts at Swansea University Medical School, staff from the Wales Institute of Social and Economic Research, Data and Methods (WISERD) at Cardiff University and specialist teams within the Welsh Government to develop new evidence which supports Prosperity for All by using the SAIL Databank at Swansea University, to link and analyse anonymised data. ADR Wales is part of the Economic and Social Research Council (part of UK Research and Innovation) funded ADR UK (grant ES/S007393/1). This work was supported by the Wales COVID-19 Evidence Centre, funded by Health and Care Research Wales. SI was funded by a BHF-Turing Cardiovascular Data Science Award (BCDSA\100005) and is funded by a University College London FB Cancer Research UK Award (C18081/A31373). RK, JAC and JACS were supported by the NIHR Bristol Biomedical Research Centre. RK, VW GDS were supported by the MRC Integrative Epidemiology Unit at the University of Bristol. RK was supported by NIHR ARC West. RD and JACS were supported by Health Data Research UK. SK is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). TM was funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). AMW is part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074 and was supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). WW is supported by the Chief Scientist's Office (CAF/01/17). CS, CS, MB AW and WW are supported by Stroke Association (SA CV 20\100018).

*The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

432 **Conflicts of interest**

433 WW is supported by the Chief Scientist's Office (CAF/01/17) and Stroke Association (SA CV
434 20100018). WW has given expert testimony to UK courts. WW served on an advisory board
435 for Bayer. NC receives funds from AstraZeneca to support membership of Data Safety and
436 Monitoring Committees for clinical trials.

437

References

- 1 Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. *Thorax* 2021; **76**: 412–20.
- 2 Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. *JAMA* 2020; **324**: 799–801.
- 3 Nannoni S, Groot R de, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis: <https://doi.org/10.1177/1747493020972922> 2020; **16**: 137–49.
- 4 Hippisley-Cox J, Patone M, Mei XW, *et al.* Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ* 2021; **374**: n1931.
- 5 Suh YJ, Hong H, Ohana M, *et al.* Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. *Radiology* 2020; **298**: E70–80.
- 6 Tan BK, Mainbourg S, Friggeri A, *et al.* Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. *Thorax* 2021; **76**: 970–9.
- 7 Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Connolly A-MF. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. *Lancet* 2021; **398**: 599–607.
- 8 Modin D, Claggett B, Sindet-Pedersen C, *et al.* Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. *Circulation*. 2020; **142**: 2080–2.
- 9 Jones KH, Ford DV, Thompson S, Lyons R. A Profile of the SAIL Databank on the UK Secure Research Platform. *Int J Popul Data Sci* 2019; **4**. DOI:10.23889/IJPD.V4I2.1134.
- 10 Wood A, Denholm R, Hollings S, *et al.* Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: Data resource. *BMJ* 2021; **373**. DOI:10.1136/bmj.n826.
- 11 Lyons J, Akbari A, Torabi F, *et al.* Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventions. *BMJ Open* 2020; **10**. DOI:10.1136/BMJOPEN-2020-043010.
- 12 Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. *Am. J. Emerg. Med.* 2020; published online April 18. DOI:10.1016/j.ajem.2020.04.048.
- 13 Clayton T, Gaskin M, Meade T. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. *Int J Epidemiol* 2011; **40**: 819–27.
- 14 Al-Aly Z. One-year Risks and Burdens of Incident Cardiovascular Disease in COVID-19: Cardiovascular Manifestations of Long COVID. 2021; published online Oct 5. DOI:10.21203/RS.3.RS-940278/V1.
- 15 Kwong JC, Schwartz KL, Campitelli MA, *et al.* Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *N Engl J Med* 2018; **378**: 345–53.
- 16 Cowan LT, Lutsey PL, Pankow JS, Cushman M, Folsom AR. Hospitalization with infection and incident venous thromboembolism: The ARIC study. *Thromb Res* 2017; **151**: 74–8.
- 17 Rogers MAM, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of Hospitalization for Venous Thromboembolism. *Circulation* 2012; **125**: 2092–9.
- 18 Mafham MM, Spata E, Goldacre R, *et al.* COVID-19 pandemic and admission rates for and

481 management of acute coronary syndromes in England. *Lancet* 2020; **396**: 381–9.

482 19 Douiri A, Muruet W, Bhalla A, *et al.* Stroke Care in the United Kingdom During the COVID-19
483 Pandemic. *Stroke* 2021; : 2125–33.

484 20 Spiegeleer A De, Bronselaer A, Teo JT, *et al.* The Effects of ARBs, ACEis, and Statins on Clinical
485 Outcomes of COVID-19 Infection Among Nursing Home Residents. *J Am Med Dir Assoc* 2020;
486 **21**: 909.

487 21 Chow R, Im J, Chiu N, *et al.* The protective association between statins use and adverse
488 outcomes among COVID-19 patients: A systematic review and meta-analysis. *PLoS One* 2021;
489 **16**: e0253576.

490 22 Horby PW, Pessoa-Amorim G, Staplin N, *et al.* Aspirin in patients admitted to hospital with
491 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *medRxiv* 2021; :
492 2021.06.08.21258132.

493

494

Table 1: Number of patients analysed in the English Trusted Research Environment, and the numbers of people (risk per 100,000 during follow up) who were and were not hospitalised within 28 days of diagnosis of COVID-19.

Characteristic		All	Number diagnosed with COVID-19 (risk per 100,000)	
			Hospitalised	Non-hospitalised
All		44,964,486	118,879 (264)	1,248,180 (2776)
Sex	Male	22,003,234	66,954 (304)	534,198 (2428)
	Female	22,961,252	51,925 (226)	713,982 (3110)
Age	18 - 29	8,185,993	2,315 (28.3)	312,359 (3,816)
	30 - 39	8,088,594	4,754 (58.8)	230,993 (2,856)
	40 - 49	7,384,405	8,951 (121)	215,874 (2,923)
	50 - 59	7,709,556	15,806 (205)	218,836 (2,839)
	60 - 69	5,920,117	18,755 (317)	117,140 (1,979)
	70 - 79	4,723,368	26,205 (555)	68,469 (1,450)
	80 - 89	2,374,255	30,852 (1,299)	57,048 (2,403)
	90+	578,198	11,241 (1,944)	27,461 (4,749)
Ethnicity	Asian or Asian British	3,594,845	13,761 (383)	160,479 (4,464)
	Black or Black British	1,540,990	5,748 (373)	37,625 (2,442)
	Mixed	678,232	1,504 (222)	19,121 (2,819)
	Other Ethnic Groups	1,455,251	2,795 (192)	25,466 (1,750)
	White	36,131,134	93,871 (260)	980,990 (2,715)
	Unknown	1,254,798	929 (74.0)	19,377 (1544)
	Missing	309,236	271 (87.6)	5,122 (1656)
Index of Multiple Deprivation	1 – 2 (most deprived)	8,817,841	33,170 (376)	316,779 (3,592)
	3 - 4	9,173,504	26,553 (289)	261,364 (2,849)
	5 - 6	9,035,766	21,500 (238)	231,658 (2,564)
	7 – 8	8,825,196	19,793 (224)	226,234 (2,564)
	9 – 10 (least deprived)	8,571,714	16,850 (197)	199,733 (2,330)
	Missing	540,465	1,013 (187)	12,412 (2,297)
Smoking status	Current	7,746,609	8,776 (113)	151,693 (1,958)
	Former	10,440,342	46,595 (446)	278,105 (2,664)
	Never	24,875,152	61,968 (249)	755,621 (3,038)
	Missing	1,902,383	1,540 (81)	62,761 (3,299)
Medical history	Arterial event(s)	1,877,562	25,629 (1,365)	54,636 (2,910)
	Venous event(s)	629,769	7,573 (1,203)	20,049 (3,184)
Number of medications	0	22,262,206	15,724 (70.6)	591,154 (2,655)
	1 - 5	20,399,092	64,583 (317)	571,391 (2,801)
	6+	2,303,188	38,572 (1,675)	85,635 (3,718)
Number of diagnoses	0	32,831,142	50,791 (155)	864,717 (2,634)
	1 - 5	11,941,404	63,667 (533)	374,473 (3,136)
	6+	191,940	4,421 (2,303)	8,990 (4,684)
Region	North West	5,782,507	22,632 (391)	244,767 (4,233)
	South East	6,742,942	12,550 (186)	115,639 (1,715)
	London	7,266,911	19,524 (269)	135,530 (1,865)
	East of England	4,184,375	8,774 (210)	67,173 (1,605)
	South West	3,629,924	5,066 (140)	57,517 (1,585)
	Missing	3,422,062	6,441 (188)	67,141 (1,962)
	Yorkshire and the Humber	4,390,661	14,733 (336)	184,983 (4,213)
	East Midlands	3,236,271	8,701 (269)	110,496 (3,414)
	West Midlands	4,588,617	14,796 (322)	195,674 (4,264)
	North East	1,720,216	5,662 (329)	69,260 (4,026)

Table 2. Numbers of arterial thrombotic, venous thromboembolic and other vascular events in the English Trusted Research Environment before and after diagnosis of COVID-19.

	No COVID-19	After hospitalised COVID-19	After non-hospitalised COVID-19	Total
Arterial thromboses				
First arterial thrombosis	252,326	2,246	5,170	259,742
Acute myocardial infarction	126,216	1,001	2,212	129,429
Ischaemic stroke	124,157	1,278	2,905	128,340
Other arterial embolism	5,535	62	223	5,820
Venous thromboembolic events				
First venous thromboembolism	57,444	810	1,812	60,066
Pulmonary embolism	30,348	579	1,226	32,153
Lower limb deep vein thrombosis	24,850	211	529	25,590
Other deep vein thrombosis	1,883	23	62	1,968
Portal vein thrombosis	513	<10	18	531
Intracranial venous thrombosis	678	<10	21	699
Other vascular events				
Heart failure	241,912	2,280	3,722	247,914
Angina	192,663	805	1,907	195,375
Transient ischaemic attack	62,124	276	789	63,189
Subarachnoid or intracranial haemorrhage	16,336	129	524	16,989

Figure 1. Age/sex/region adjusted and maximally adjusted hazard ratios (log scale) for different arterial thrombotic, and venous thromboembolic and other vascular events by time since diagnosis of COVID-19.

508 **Figure 2 Hazard ratios (log scale) for first arterial event after COVID-19 by time since diagnosis, overall and stratified by whether hospitalised with**
 509 **COVID-19, prior history of an arterial event, age, sex and ethnicity.**

511 **Figure 3 Hazard ratios for first venous event after COVID-19 by time since diagnosis, overall and stratified by whether hospitalised with COVID-19, prior**
 512 **history of an venous event, age, sex and ethnicity.**

513

514 **Figure 4. Estimated absolute increase in risk of arterial and venous events over time since diagnosis of COVID-19, compared with no COVID-19 diagnosis.**

515

516

517 **Supplementary Material**

518 **Additional details of statistical methods**

519 In general, we estimated hazard ratios using separate models for age group and, in the relevant analyses, for hospitalised and non-hospitalised COVID-19.
520 Overall results were then derived by combining hazard ratios across age groups using inverse-variance meta-analysis. The same set of covariates was
521 adjusted for in each age group before results were combined. In some analyses, limited numbers of outcome events after COVID-19 meant that the younger
522 age groups had to be combined in order to fit maximally adjusted models. For some models examining outcomes after hospitalised COVID-19, all age groups
523 had to be combined because small numbers of outcome events after hospitalised COVID-19 made it impossible to identify a set of covariates that could be
524 adjusted for across all groups, and/or some regions had to be merged.

525

526

527 **Supplementary Table 1. Derivation of COVID-19 variables in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

528 All codelists are available in the GitHub for England: https://github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes
529 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes
530

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Exposure				
COVID-19 diagnosis date	SGSS, GDPPR, deaths registry, HES APC, HES CC, CHESS, SUS	PATD (Pillar 1 & 2), PEDW, WLGP	Minimum date of confirmed COVID-19 event post index date. A record of a positive COVID-19 PCR antigen test or a record of confirmed diagnosis in primary care general practice or secondary care hospital admission records.	exp_confirmed_covid19_date
COVID-19 infection severity	SGSS, GDPPR, deaths registry, HES APC, HES CC, CHESS, SUS	PATD (Pillar 1 & 2), PEDW, WLGP	COVID-19 infection with hospitalisation was defined as a hospital admission record with confirmed COVID-19 diagnosis in the primary position within 28 days of first COVID-19 infection. COVID-19 infection without hospitalisation was defined as a confirmed COVID-19 diagnosis in the primary position within 28 days of first COVID-19 infection without a hospital admission record.	exp_confirmed_covid_phenotype

531 Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for pandemic planning and research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), , ADDE (Annual District
532 Death Extract), PEDW (Patient Episode Dataset for Wales), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), PATD (COVID-19 Test Results), CHESS (COVID-19 Hospitalisation in
533 England Surveillance System), SGSS (Covid-19 Second Generation Surveillance System).
534

535 **Supplementary Table 2. Derivation of major outcomes in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

536 All codelists are available in the GitHub for England https://github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes
 537 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes
 538

Outcome	Data Sources (NHS Digital)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Arterial thromboses				
Myocardial infarction	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_AMI
Ischaemic stroke*	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_stroke_isch
Other arterial thromboembolism	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_other_arterial_embolism
Venous thromboembolic events				
Pulmonary embolism	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_PE
Lower limb deep vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_DVT_DVT, out_DVT_pregnancy
Other deep vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_other_DVT
Portal vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_portal_vein_thrombosis
Intracranial venous thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_ICVT, out_ICVT_pregnancy
Other vascular events				
Intracranial or subarachnoid haemorrhage	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_stroke_SAH_HS
Heart failure	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_HF
Angina	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_angina
Transient ischemic attack	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_stroke_TIA

539 Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for pandemic planning and research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), , ADDE (Annual District
 540 Death Extract), PEDW (Patient Episode Dataset for Wales), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), PATD (COVID-19 Test Results), CHESS (COVID-19 Hospitalisation in
 541 England Surveillance System), SGSS (Covid-19 Second Generation Surveillance System).
 542

543 **Supplementary Table 3. Derivation of covariates in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

544 All codelists are available in the GitHub for England: github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes

545 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes

546

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Demographic characteristics				
Patient pseudoidentifier	All	All	Patient pseudoidentifier	NHS_NUMBER_DEID
death date	GDPPR, HES APC, deaths registry	C19_Cohort20 (WDSO, ADDE, ADDD, CDDO)	Earliest date of death recorded in specified data sources	death_date
sex	GDPPR, HES APC, HES OP, HES AE	C19_Cohort20 (WDSO)	Binary indicator for male or female (most recent record prior to index date and will initially select from primary care if possible)	cov_sex
age	GDPPR, HES APC, HES OP, HES AE	C19_Cohort20 (WDSO)	Age in years calculated on index date (will initially select from primary care if possible)	cov_age
ethnicity	GDPPR, HES APC, HES OP, HES AE	CCDS, CVVD, EDDS, ICNC, MIDS, NCCH, OPRD, PEDW, WASD	Patient ethnicity (most recent record prior to index date from primary care - Black or Black British, Asian or Asian British, Other, Mixed, Missing, Unknown)	cov_ethncity
smoking status	GDPPR	WLGP	Most recent smoking status (Smoker, Ex-smoker, Never-smoker) prior to index date	cov_smoking_status
deprivation	English indices of deprivation year 2019	C19_Cohort20 (WDSO, PEDW)	Most recent decile of deprivation prior to index date, defined using IMD	cov_deprivation
region of residence	English indices of deprivation year 2019	N/A	Most recent residence prior to index date (East of England, London, Midlands, NE and Yorkshire, North West, South East, South West, Scotland, Wales)	cov_region
Medications				
antiplatelet	primary care medications	WDDS	Binary indicator for antiplatelet medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_antiplatelet_meds
lipid lowering	primary care medications	WDDS	Binary indicator for lipid lowering medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_lipid_meds
anticoagulation	primary care medications	WDDS	Binary indicator for anticoagulation medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_anticoagulation_meds
combined oral contraceptive pill	primary care medications	WDDS	Binary indicator for COCP medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_cocp_meds
blood pressure lowering	primary care medications	WDDS	Binary indicator for bp lowering medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_ever_icvt
hormone replacement therapy	primary care medications	WDDS	Binary indicator for HRT medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_hrt_meds

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Past history of disease				
acute myocardial infection	GDPPR, HES APC	WLGP, PEDW	Binary indicator for acute myocardial infarction prior to index date, defined using condition diagnosis code only	cov_ever_ami
embolism	GDPPR, HES APC	WLGP, PEDW	Binary indicator for pulmonary embolism or DVT prior to index date, defined using condition diagnosis code only	cov_ever_pe_vt
intracranial venous thrombosis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for ICVT prior to index date, defined using condition diagnosis code only	cov_ever_icvt
any stroke	GDPPR, HES APC	WLGP, PEDW	Binary indicator for stroke (ischaemic stroke, intracranial haemorrhage, or stroke of unknown type) prior to index date, defined using condition diagnosis code only	cov_ever_all_stroke
thrombophilia	GDPPR, HES APC	WLGP, PEDW	Binary indicator for thrombophilia prior to index date, defined using condition diagnosis code only	cov_ever_thrombophilia
thrombocytopenia, TTP	GDPPR, HES APC	WLGP, PEDW	Binary indicator for thrombocytopenia prior to index date, defined using condition diagnosis code only	cov_ever_tcp
dementia	GDPPR, HES APC	WLGP, PEDW	Binary indicator for dementia prior to index date, defined using condition diagnosis code only	cov_ever_dementia
liver disease	GDPPR, HES APC	WLGP, PEDW	Binary indicator for liver disease prior to index date, defined using condition diagnosis code only	cov_ever_liver_disease
chronic kidney disease	GDPPR, HES APC	WLGP, PEDW	Binary indicator for chronic kidney disease prior to index date, defined using condition diagnosis code only	cov_ever_ckd
cancer	GDPPR, HES APC	WLGP, PEDW	Binary indicator for cancer prior to index date, defined using condition diagnosis code only	cov_ever_cancer
hypertension	GDPPR, HES APC, primary care medications	WLGP, PEDW, WDDS	Binary indicator for hypertension prior to index date, defined using either condition diagnosis code or drug use	cov_ever_hypertension
diabetes	GDPPR, HES APC, primary care medications	WLGP, PEDW, WDDS	Binary indicator for diabetes prior to index date, defined using either condition diagnosis code or drug use	cov_ever_diabetes
obesity	GDPPR, HES APC	WLGP, PEDW	Binary indicator for obesity prior to index date, defined using either condition diagnosis code or measurement	cov_ever_obesity
depression	GDPPR, HES APC	WLGP, PEDW	Binary indicator for depression prior to index date, defined using condition diagnosis code only	cov_ever_depression
COPD	GDPPR, HES APC	WLGP, PEDW	Binary indicator for chronic obstructive pulmonary disease prior to index date, defined using condition diagnosis code only	cov_ever_copd
number of unique disorders	GDPPR	WLGP	Number of consultations for different ailments/conditions/diseases in the year prior to index date	cov_n_disorder
disseminated	GDPPR, HES APC	WLGP, PEDW	Binary indicator for disseminated intravascular coagulation prior to index date,	cov_ever_other_arterial_e

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
intravascular coagulation			defined using condition diagnosis code only	mbolism
mesenteric thrombus	GDPPR, HES APC	WLGP, PEDW	Binary indicator for mesenteric thrombus prior to index date, defined using condition diagnosis code only	cov_ever_dic
artery dissection	GDPPR, HES APC	WLGP, PEDW	Binary indicator for artery dissection prior to index date, defined using condition diagnosis code only	cov_ever_mesenteric_thro mbus
life threatening arrhythmias	GDPPR, HES APC	WLGP, PEDW	Binary indicator for life threatening arrhythmias prior to index date, defined using condition diagnosis code only	cov_ever_artery_dissect
cardiomyopathy	GDPPR, HES APC	WLGP, PEDW	Binary indicator for cardiomyopathy prior to index date, defined using condition diagnosis code only	cov_ever_life_arrhythmia
heart failure	GDPPR, HES APC	WLGP, PEDW	Binary indicator for heart failure prior to index date, defined using condition diagnosis code only	cov_ever_cardiomyopathy
pericarditis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for pericarditis prior to index date, defined using condition diagnosis code only	cov_ever_hf
myocarditis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for myocarditis prior to index date, defined using condition diagnosis code only	cov_ever_pericarditis
major surgery in the last year	HES APC	PEDW	Binary indicator for major surgery within a year prior to index date, defined using condition diagnosis code only	cov_ever_myocarditis

Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for Pandemic Planning and Research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), AE (Accident and Emergency), WDSD (Welsh Demographic Service Dataset), ADDE (Annual District Death Extract), ADDD (Annual District Death Daily), CDD (COVID-19 Consolidated Deaths), CCDS (Critical Care Dataset), CVVD (Covid Vaccination Dataset), EDDS (Emergency Department Dataset), ICNC (Intensive Care National Audit and Research Centre - Covid19), MIDS (Maternity Indicators Dataset), NCCH (National Community Child Health), OPRD (Outpatient Referral), PEDW (Patient Episode Dataset for Wales), WASD (Welsh Ambulance Services NHS Trust), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), WDDS (Welsh Dispensing Dataset).

Supplementary Table 4. Number of patients analysed in the Welsh SAIL Databank and the number of people (risk per 100,000 during follow up) who were and were not hospitalised within 28 days of diagnosis of COVID-19.

Characteristic		All	Diagnosed with COVID-19	
			Hospitalised N (per 100,000)	Non-hospitalised N (per 100,000)
All		2,615,854	12,051 (460.7)	66,661 (2,548.3)
Sex	Male	1,297,835	6,124 (471.9)	28,274 (2,178.6)
	Female	1,318,019	5,927 (449.7)	38,387 (2,912.5)
Age in decades	18-29	480,489	333 (69.3)	17,881 (3721.4)
	30-39	416,955	414 (99.3)	12,649 (3033.7)
	40-49	395,768	740 (187)	12,401 (3133.4)
	50-59	458,138	1,329 (290.1)	12,648 (2760.7)
	60-69	379,681	1,778 (468.3)	5,580 (1469.7)
	70-79	309,633	3,022 (976)	2,702 (872.6)
	80-89	144,198	3,337 (2314.2)	1,921 (1332.2)
	90+	30,992	1,098 (3542.8)	879 (2836.2)
Ethnicity	Asian or Asian British	42,574	151 (354.7)	1,544 (3626.6)
	Black or Black British	11,925	36 (301.9)	393 (3295.6)
	Missing	579,378	1,522 (262.7)	13,470 (2324.9)
	Mixed	15,931	47 (295)	435 (2730.5)
	Other Ethnic Groups	15,119	38 (251.3)	423 (2797.8)
	White	1,950,926	10,257 (525.8)	50,396 (2583.2)
Index of Multiple Deprivation	1 (most deprived)	478,172	2,815 (588.7)	14,993 (3135.5)
	2	485,212	2,574 (530.5)	14,718 (3033.3)
	3	492,738	2,011 (408.1)	10,947 (2221.7)
	4	489,763	2,007 (409.8)	9,998 (2041.4)
	5 (least deprived)	494,009	1,968 (398.4)	11,510 (2329.9)
	Missing	175,960	676 (384.2)	4,495 (2554.6)
Smoking status	Current	560,733	2,100 (374.5)	11,634 (2074.8)
	Former	160,266	1,439 (897.9)	3,398 (2120.2)
	Missing	513,315	1,974 (384.6)	10,126 (1972.7)
	Never	1,381,540	6,538 (473.2)	41,503 (3004.1)
Medical history	Arterial event(s)	120,085	2,575 (2,144.3)	2,097 (1,746.3)
	Venous event(s)	38,072	732 (1,922.7)	807 (2,119.7)
Number of medications	0	1,079,924	1,268 (117.4)	28,028 (2,595.4)
	1-5	1,367,038	7,011 (512.9)	35,035 (2,562.8)
	6+	168,891	3,772 (2,233.4)	3,598 (2,130.4)
Number of diagnosis	0	2,219,698	6,851 (308.6)	57,853 (2,606.3)
	1-5	248,255	3,501 (1,410.2)	5,801 (2,336.7)
	6+	147,900	1,699 (1,148.7)	3,007 (2,033.1)

556 **Supplementary Table 5. Hazard ratios (95% CI) compared with no COVID-19 for different arterial thromboses (acute myocardial infarction and ischaemic**
557 **stroke), venous thromboembolism events (pulmonary embolism and deep vein thrombosis) and other vascular events, according to time since diagnosis**
558 **of COVID-19. All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
Acute myocardial infarction							
All	17.2 (16.3-18.1)	3.37 (2.99-3.80)	2.37 (2.12-2.64)	1.57 (1.41-1.76)	1.44 (1.26-1.65)	1.17 (1.07-1.29)	1.21 (1.03-1.41)
All, unadjusted	22.1 (21.0-23.2)	4.31 (3.82-4.87)	2.99 (2.68-3.34)	2.03 (1.82-2.27)	1.97 (1.72-2.26)	1.68 (1.53-1.84)	1.75 (1.50-2.05)
Hospitalised COVID-19*	13.7 (12.3-15.3)	6.64 (5.58-7.89)	4.28 (3.60-5.09)	2.42 (2.00-2.92)	1.70 (1.32-2.19)	1.44 (1.23-1.68)	1.39 (1.12-1.72)
Non-hospitalised COVID-19*	17.9 (16.9-19.0)	2.19 (1.85-2.60)	1.79 (1.55-2.06)	1.31 (1.15-1.51)	1.37 (1.16-1.61)	1.06 (0.94-1.19)	1.03 (0.83-1.28)
Ischaemic stroke							
All	23.0 (22.0-24.1)	4.22 (3.78-4.72)	3.17 (2.88-3.50)	2.47 (2.25-2.70)	1.92 (1.70-2.17)	1.58 (1.45-1.71)	1.62 (1.42-1.86)
All, unadjusted	28.1 (26.8-29.4)	5.08 (4.54-5.67)	3.78 (3.42-4.16)	3.02 (2.75-3.31)	2.43 (2.15-2.74)	2.03 (1.87-2.21)	2.15 (1.88-2.47)
Hospitalised COVID-19	15.3 (13.9-16.9)	6.84 (5.79-8.09)	5.87 (5.07-6.80)	4.10 (3.54-4.75)	2.47 (2.01-3.04)	1.64 (1.42-1.90)	1.62 (1.33-1.98)
Non-hospitalised COVID-19	23.2 (22.1-24.4)	2.86 (2.46-3.32)	2.10 (1.84-2.39)	1.74 (1.54-1.95)	1.50 (1.30-1.74)	1.35 (1.22-1.49)	1.33 (1.10-1.59)
Deep vein thrombosis							
All	10.8 (9.32-12.5)	4.00 (3.10-5.15)	4.80 (4.03-5.73)	3.20 (2.68-3.82)	2.55 (2.01-3.25)	1.95 (1.65-2.32)	1.99 (1.49-2.65)
All, unadjusted	12.3 (10.6-14.3)	4.56 (3.54-5.88)	5.47 (4.59-6.52)	3.71 (3.11-4.43)	3.12 (2.45-3.97)	2.48 (2.09-2.94)	2.61 (1.96-3.48)
Hospitalised COVID-19	6.44 (4.28-9.70)	5.03 (3.03-8.35)	6.20 (4.33-8.88)	7.29 (5.56-9.56)	4.20 (2.83-6.22)	2.42 (1.81-3.22)	1.89 (1.19-3.00)
Non-hospitalised COVID-19	11.3 (9.65-13.2)	3.50 (2.61-4.69)	4.23 (3.46-5.17)	2.18 (1.73-2.75)	1.95 (1.44-2.64)	1.64 (1.33-2.03)	1.88 (1.31-2.71)
Pulmonary embolism							
All	33.2 (30.7-35.9)	9.97 (8.57-11.6)	10.5 (9.44-11.8)	5.55 (4.91-6.27)	3.22 (2.66-3.90)	2.41 (2.10-2.76)	1.61 (1.23-2.12)
All, unadjusted	39.7 (36.7-42.9)	11.7 (10.1-13.7)	12.5 (11.2-14.0)	6.76 (5.98-7.63)	4.11 (3.39-4.97)	3.17 (2.76-3.63)	2.22 (1.69-2.92)
Hospitalised COVID-19	19.3 (15.7-23.6)	16.6 (13.1-21.1)	21.0 (17.8-24.9)	14.4 (12.2-17.0)	5.67 (4.23-7.60)	2.76 (2.19-3.48)	1.40 (0.90-2.18)
Non-hospitalised COVID-19	34.5 (31.7-37.5)	7.06 (5.80-8.58)	7.16 (6.21-8.26)	3.07 (2.57-3.67)	2.27 (1.76-2.92)	2.08 (1.76-2.47)	1.60 (1.13-2.27)
Haemorrhagic stroke (intracerebral or subarachnoid haemorrhage)							
All	31.7 (28.6-35.2)	2.83 (1.97-4.05)	1.92 (1.39-2.67)	1.86 (1.41-2.45)	1.99 (1.43-2.76)	1.57 (1.27-1.95)	1.80 (1.29-2.50)
All, unadjusted	40.2 (37.3-43.3)	3.51 (2.71-4.54)	2.43 (1.93-3.07)	2.28 (1.87-2.78)	2.78 (2.19-3.52)	2.09 (1.79-2.44)	2.54 (2.01-3.20)
Hospitalised COVID-19	12.4 (8.94-17.2)	3.97 (1.78-8.84)	2.41 (1.21-4.83)	2.22 (1.23-4.01)	4.85 (3.01-7.81)	1.81 (1.19-2.75)	1.17 (0.59-2.35)
Non-hospitalised COVID-19	37.3 (33.4-41.6)	2.46 (1.60-3.78)	1.74 (1.18-2.56)	1.64 (1.18-2.28)	1.21 (0.76-1.92)	1.46 (1.13-1.89)	2.25 (1.55-3.27)
Transient ischaemic attack							
All	7.79 (6.99-8.68)	2.05 (1.64-2.56)	1.44 (1.18-1.76)	1.41 (1.19-1.66)	1.39 (1.15-1.69)	1.17 (1.03-1.34)	1.38 (1.13-1.69)
All, unadjusted	9.23 (8.54-9.97)	2.43 (2.08-2.85)	1.68 (1.46-1.94)	1.71 (1.51-1.92)	1.79 (1.56-2.05)	1.53 (1.39-1.67)	1.80 (1.56-2.08)
Hospitalised COVID-19	5.82 (4.54-7.45)	1.97 (1.22-3.17)	1.75 (1.15-2.67)	2.02 (1.47-2.77)	1.85 (1.27-2.70)	1.24 (0.97-1.58)	1.60 (1.19-2.16)
Non-hospitalised COVID-19	8.44 (7.48-9.52)	2.07 (1.61-2.66)	1.34 (1.06-1.69)	1.27 (1.04-1.54)	1.32 (1.05-1.66)	1.13 (0.97-1.32)	1.20 (0.91-1.58)

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
Angina							
All	6.37 (5.94-6.83)	1.97 (1.73-2.25)	1.72 (1.55-1.92)	1.45 (1.32-1.60)	1.22 (1.07-1.38)	1.08 (1.00-1.18)	1.07 (0.93-1.23)
All, unadjusted	8.12 (7.73-8.53)	2.47 (2.25-2.72)	2.14 (1.98-2.31)	1.84 (1.72-1.98)	1.62 (1.48-1.77)	1.50 (1.41-1.59)	1.53 (1.39-1.69)
Hospitalised COVID-19	5.31 (4.58-6.15)	3.01 (2.42-3.73)	2.58 (2.13-3.12)	1.61 (1.32-1.96)	1.45 (1.14-1.83)	1.13 (0.98-1.31)	0.98 (0.79-1.21)
Non-hospitalised COVID-19	6.72 (6.20-7.28)	1.48 (1.24-1.77)	1.44 (1.26-1.64)	1.40 (1.25-1.56)	1.15 (0.99-1.34)	1.06 (0.96-1.18)	1.17 (0.98-1.41)
Heart failure							
All	9.40 (8.99-9.84)	2.01 (1.81-2.24)	2.04 (1.89-2.21)	1.98 (1.85-2.11)	1.89 (1.74-2.04)	1.42 (1.35-1.50)	1.27 (1.15-1.39)
All, unadjusted	13.8 (13.4-14.3)	2.86 (2.65-3.08)	2.87 (2.71-3.04)	2.85 (2.72-2.99)	2.96 (2.79-3.12)	2.31 (2.22-2.40)	2.19 (2.05-2.34)
Hospitalised COVID-19	8.21 (7.56-8.93)	2.50 (2.10-2.97)	3.27 (2.89-3.70)	3.03 (2.72-3.37)	2.62 (2.30-2.97)	1.86 (1.71-2.02)	1.45 (1.28-1.66)
Non-hospitalised COVID-19	9.92 (9.39-10.5)	1.73 (1.51-1.98)	1.57 (1.41-1.74)	1.62 (1.49-1.76)	1.59 (1.44-1.76)	1.22 (1.13-1.31)	1.10 (0.96-1.26)

559

560 **Supplementary Table 6. Hazard ratios (95% CI) compared with no COVID-19 for first arterial thrombosis, according to time since diagnosis of COVID-19.**
561 **All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
All	21.7 (21.0-22.4)	3.87 (3.58-4.19)	2.80 (2.61-3.01)	2.00 (1.87-2.14)	1.58 (1.45-1.73)	1.34 (1.27-1.43)	1.34 (1.21-1.48)
All, unadjusted	27.9 (27.0-28.8)	4.90 (4.53-5.30)	3.50 (3.27-3.76)	2.57 (2.40-2.75)	2.14 (1.96-2.34)	1.88 (1.77-2.00)	1.92 (1.73-2.12)
Hospitalised COVID-19 ¹	14.2 (13.2-15.3)	6.60 (5.85-7.44)	4.97 (4.43-5.56)	3.25 (2.90-3.66)	2.00 (1.70-2.36)	1.50 (1.35-1.68)	1.46 (1.26-1.70)
Non-hospitalised COVID-19	22.0 (21.2-22.9)	2.65 (2.37-2.96)	2.03 (1.84-2.23)	1.58 (1.45-1.73)	1.42 (1.27-1.59)	1.24 (1.15-1.34)	1.21 (1.05-1.40)
Prior history of event		5.68 (5.40-5.98)			1.42 (1.34-1.51)		
No prior history of event		10.6 (10.2-11.0)			1.72 (1.63-1.82)		
Age <40 years	16.7 (12.7-22.0)	3.30 (1.77-6.16)	1.31 (0.62-2.75)	1.07 (0.53-2.14)	0.90 (0.33-2.40)	1.56 (0.93-2.61)	0.94 (0.30-2.93)
Age 40-59 years	19.3 (17.8-21.0)	3.36 (2.75-4.12)	2.72 (2.30-3.22)	1.92 (1.62-2.28)	1.77 (1.41-2.22)	1.39 (1.18-1.64)	1.86 (1.48-2.35)
Age 60-79 years	26.8 (25.6-28.2)	4.61 (4.09-5.19)	3.03 (2.71-3.39)	2.20 (1.98-2.45)	1.61 (1.38-1.87)	1.38 (1.25-1.53)	1.39 (1.18-1.64)
Age 80+ years	18.1 (17.2-19.0)	3.40 (3.00-3.85)	2.67 (2.39-2.98)	1.89 (1.70-2.10)	1.54 (1.35-1.75)	1.30 (1.19-1.42)	1.12 (0.96-1.31)
Females	20.5 (19.5-21.5)	3.36 (2.97-3.81)	2.61 (2.35-2.91)	1.91 (1.72-2.11)	1.55 (1.36-1.77)	1.27 (1.16-1.38)	1.19 (1.02-1.39)
Males	22.9 (21.9-23.8)	4.33 (3.92-4.79)	3.00 (2.73-3.29)	2.10 (1.91-2.30)	1.64 (1.45-1.86)	1.43 (1.32-1.55)	1.50 (1.31-1.71)
White		7.66 (7.42-7.92)			1.47 (1.40-1.53)		
Black or Black British		10.4 (8.70-12.5)			1.96 (1.60-2.41)		
Asian or Asian British		9.35 (8.48-10.3)			1.64 (1.43-1.89)		
Other ethnic groups		9.04 (6.84-12.0)			1.97 (1.39-2.79)		
Mixed ethnicity		8.27 (5.88-11.6)			1.24 (0.77-1.99)		

562

563

564 **Supplementary Table 7. Hazard ratios (95% CI) compared with no COVID-19 for first venous thromboembolism, according to time since diagnosis of**
565 **COVID-19. All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
All	33.2 (31.3-35.2)	8.52 (7.59-9.58)	7.95 (7.28-8.68)	4.26 (3.86-4.69)	2.96 (2.58-3.41)	2.20 (1.99-2.44)	1.80 (1.50-2.17)
All, unadjusted	40.3 (38.0-42.7)	10.1 (9.03-11.4)	9.44 (8.65-10.3)	5.19 (4.71-5.72)	3.79 (3.29-4.36)	2.92 (2.64-3.23)	2.49 (2.07-3.00)
Hospitalised COVID-19	14.5 (12.2-17.4)	11.5 (9.22-14.2)	14.3 (12.3-16.7)	11.2 (9.72-12.9)	5.40 (4.31-6.77)	2.63 (2.19-3.14)	1.57 (1.14-2.16)
Non-hospitalised COVID-19	24.4 (22.7-26.3)	5.46 (4.66-6.40)	6.05 (5.39-6.78)	2.56 (2.22-2.95)	2.22 (1.84-2.68)	1.98 (1.74-2.25)	1.77 (1.38-2.27)
Prior history of event		6.21 (5.30-7.27)				1.72 (1.45-2.05)	
No prior history of event		12.1 (11.5-12.8)				2.87 (2.68-3.08)	
Age <40 years	18.6 (14.9-23.1)	5.95 (4.04-8.76)	5.62 (4.16-7.58)	2.94 (2.06-4.18)	2.09 (1.21-3.61)	2.98 (2.17-4.11)	2.85 (1.61-5.05)
Age 40-59 years	31.8 (28.3-35.7)	11.8 (9.80-14.3)	9.61 (8.26-11.2)	3.68 (3.00-4.52)	2.44 (1.78-3.36)	2.18 (1.76-2.70)	1.68 (1.11-2.53)
Age 60-79 years	42.2 (38.5-46.2)	9.27 (7.64-11.2)	9.06 (7.88-10.4)	5.07 (4.34-5.91)	3.57 (2.86-4.45)	2.40 (2.03-2.84)	2.10 (1.56-2.82)
Age 80+ years	27.9 (24.7-31.5)	3.75 (2.76-5.10)	4.81 (3.90-5.93)	4.23 (3.53-5.06)	2.91 (2.29-3.71)	1.81 (1.51-2.17)	1.38 (0.97-1.96)
Females	29.7 (27.3-32.3)	6.84 (5.77-8.12)	6.87 (6.04-7.81)	4.22 (3.70-4.82)	3.00 (2.49-3.63)	2.08 (1.81-2.39)	1.91 (1.49-2.44)
Males	38.2 (35.2-41.5)	11.0 (9.41-12.9)	9.50 (8.43-10.7)	4.40 (3.81-5.09)	3.08 (2.49-3.79)	2.41 (2.08-2.80)	1.76 (1.32-2.34)
White		10.1 (9.56-10.7)				2.49 (2.32-2.66)	
Black or Black British		18.0 (14.2-22.8)				2.68 (1.94-3.70)	
Asian or Asian British		17.6 (14.1-21.8)				4.05 (3.09-5.31)	
Other ethnic groups		15.9 (9.13-27.8)				5.62 (3.28-9.63)	
Mixed ethnicity		15.7 (9.78-25.1)				2.52 (1.29-4.93)	

566

567 **Supplementary Figure 1. Maximally adjusted hazard ratios (log scale) for different arterial thrombotic,**
 568 **and venous thromboembolic and other vascular events by time since diagnosis of COVID-19, separately**
 569 **for hospitalised and non-hospitalised COVID-19.**

570

571 **Supplementary Figure 2. Estimated absolute increase in risk of arterial and venous events over time since diagnosis of COVID-19, compared with no**
572 **COVID-19 diagnosis, after excluding the risk during the first 28 days since diagnosis**

573